| DC10559 |
Derazantinib (ARQ 087)
Featured
|
Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. |
|
| DCAPI1475 |
Dexrazoxane Hydrochloride |
Dexrazoxane Hydrochloride |
|
| DC7114 |
Dinaciclib (SCH727965)
Featured
|
Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. |
|
| DC9588 |
Dofequidar (fumarate) |
Dofequidar fumarate(MS-209 fumarate), an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.
|
|
| DC4157 |
Dovitinib (TKI258, CHIR258)
Featured
|
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
|
| DC10313 |
Dovitinib lactate |
Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. |
|
| DC11726 |
Milademetan
Featured
|
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis. |
|
| DC8404 |
E3330
Featured
|
E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity. |
|
| DC7128 |
Lucitanib(E3810)
Featured
|
E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. |
|
| DC10563 |
E-7046
Featured
|
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC5065 |
Golvatinib (E7050)
Featured
|
E-7050 is hepatocyte growth factor receptors (HGFR). |
|
| DC7116 |
E7080 (Lenvatinib)
Featured
|
E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
|
| DC11062 |
E7107 |
E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
|
| DC9983 |
E-7449
Featured
|
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. |
|
| DCAPI1441 |
Seocalcitol |
EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca |
|
| DC9755 |
eFT508(Tomivosertib)
Featured
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
|
| DC10182 |
Elacestrant (dihydrochloride)
Featured
|
Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. |
|
| DC8301 |
Elacridar
Featured
|
Elacridar is an orally selectly potent P-glycoprotein (P-gp/ABCG1) inhibitor. |
|
| DC11192 |
Elacytarabine |
Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity. |
|
| DC3156 |
Elesclomol (STA-4783)
Featured
|
Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells.. |
|
| DC8265 |
Endoxifen
Featured
|
Endoxifen is a Estrogen receptor α (ERα) ligand; potent antiestrogen,an active metabolite of the cancer drug tamoxifen. |
|
| DC6909 |
Entinostat (MS-275)
Featured
|
Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2. |
|
| DC8300 |
Entrectinib (RXDX-101)
Featured
|
Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions. |
|
| DC5057 |
Enzastaurin (LY317615)
Featured
|
Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3. |
|
| DC7927 |
EPZ011989
Featured
|
EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
|
| DC11387 |
Erdafitinib
Featured
|
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively. |
|
| DCAPI1539 |
Eribulin Mesylate
Featured
|
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. |
|
| DCAPI1516 |
Eribulin |
Eribulin Mesylate (E7389 Mesylate), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. |
|
| DC2101 |
Erlotinib free base
Featured
|
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
| DC3139 |
Erlotinib hydrochloride
Featured
|
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
|
